Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2401 plus nivolumab in advanced adrenal malignancies
NL-OMON52906Phase 2Completed
- Sponsor
- Enterome
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eo2401 and nivolumab in adrenal cancer (ACC), pheochromocytoma and malignant paraganglioma (7 cohorts), sponsored by Enterome. Primary endpoints: Safety and tolerability of EO2401 in combination with nivolumab and Progression-free survival rate at 6 months. Started Jan 2021; status: completed.
02
Drugs
eo2401nivolumab
03
Conditions
adrenal cancer (ACC)pheochromocytomamalignant paraganglioma
Beyond the preview
Go deeper on NL-OMON52906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52906.